<DOC>
	<DOC>NCT02527681</DOC>
	<brief_summary>The primary objective is to characterize the pharmacokinetics of single doses of ceftobiprole in neonates and infants aged ≤ 3 months. The secondary objective is to evaluate safety and tolerability of ceftobiprole in neonates and infants aged ≤ 3 months.</brief_summary>
	<brief_title>Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Ceftobiprole</mesh_term>
	<mesh_term>Ceftobiprole medocaril</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Neonates and infants ≤ 3 months, with gestational age ≥ 28 weeks Documented or presumed (or at risk of) bacterial infections, and currently receiving antibiotic treatment Expected to survive beyond the first 7 days after enrolment Sufficient vascular access to receive study drug, and to allow blood sampling at a site separate from the study drug infusion site Parent's / legally acceptable representative's informed consent to participate in the study Major birth defect or malformation syndrome Proven presence of an immunodeficiency HIV or other congenital viral or fungal infection Significant laboratory abnormalities including: Haematocrit &lt; 20%; Absolute neutrophil count &lt; 0.5⋅10⁹/L; Platelet count &lt; 50⋅10⁹/L; Alanine aminotransferase or aspartate aminotransferase &gt; 3 times the agespecific upper limit of normal Impaired renal function or known significant renal disease Any condition which would make the subject or caregiver, in the opinion of the investigator, unsuitable for the study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>